logo-loader
viewImugene Ltd

Imugene obtains FDA guidance for KEY-Vaxx immunotherapy clinical development plan

Imugene Ltd (ASX:IMU) managing director & CEO Leslie Chong updates Proactive Investors on the clinical-stage immuno-oncology company’s development of its KEY-Vaxx cancer vaccine.
 
The company had a pre-investigational new drug meeting with the US Food and Drug Administration (FDA) to obtain regulatory guidance and agreement on the preclinical chemistry and controls for KEY-Vaxx’s clinical development plan. 
 
“They approved everything we wanted to do and even ratcheted us back from doing some of the tests because it wasn’t necessary,” says Chong. 
 
She continues, “given that the FDA fully approved our pre-clinical plan, it really bodes well for the safety of this drug.”

Quick facts: Imugene Ltd

Price: 0.055 AUD

ASX:IMU
Market: ASX
Market Cap: $239.79 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Imugene gets green light to start phase-1 clinical trial of new cancer...

Imugene Ltd's (ASX:IMU) Leslie Chong speaks to Proactive's Andrew Scott following the news it's received a second Human Research Ethics Committee approval to begin a phase-I clinical trial of its cancer checkpoint immunotherapy candidate, PD1-Vaxx. Ethics approval is confirmation that Imugene...

3 weeks, 3 days ago

2 min read